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Long-term Outcome after Bare-Metal or Drug-Eluting Stenting for
Allograft Coronary Artery Disease
Farzin Beygui, Shaida Varnous, Gilles Montalescot, Flor Fernandez, Jean-
Philippe Collet, Pascal Leprince, Claude Lefeuvre, Alain Pavie, Jean-Phi-
lippe Metzger, Iradj Gandjbakhch
Groupe hospitalier pitié salpêtrière, cardiologie, Paris, France
Percutaneous coronary intervention (PCI) with BMS has been reported to
be associated with poor outcome in heart transplant recipient. We aimed to
assess the outcome of successful PCI with bare-metal stents (BMS) or drug-
eluting stents (DES) in heart transplant recipients.
Methods: Ninety-four consecutive heart transplant recipients with suc-
cessful PCI of de novo lesions with BMS (n=53) or DES (n=60) were prospec-
tively followed-up for 41.8±31.5 months after the PCI.
Results: The lesion-based analysis within 12 months after PCI showed a
marked reduction of target lesion revascularization (TLR) and restenosis rates
by the use of DES (6.9% versus 26.4%, p=0.005 and 7.1% versus 32.1%,
p=0.001 respectively). The patient-based multivariable analysis identified
transplantation to PCI time (HR 1.1 per month), absence of antihypertensive
therapy (HR 4.53) and left ventricular ejection fraction (HR 0.95 per percent)
but not stent type as independent correlates of death. BMS (HR 3.79) and tac-
rolimus use (HR 8.32) were independent correlates of TLR.
Conclusions: Compared to BMS, DES are associated with a marked reduc-
tion in rates of restenosis and TLR in heart transplant recipients and may be
recommended despite the absence of a relationship between the stent type and
survival. Early treatment of allograft vasculopathy, extensive antihypertensive
therapy and left ventricular function preservation, appear as major goals of
treatment to improve long-term survival in such patients. 
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A standardized approach of aortic valve sparing combining root remo-
deling and aortic annuloplasty: impact of additional cusp repair?
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Vasculaire, Montfermeil, France – (3) CHU Michallon, Grenoble, France –
(4) Clinique Saint Gatien, Tours, France – (5) CHU Bocage, Dijon,
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Objectives: Aortic valve sparing is gaining increasing acceptance, however
association with cusp repair may jeopardize its results. We studied patients
operated electively with a standardized valve sparing approach with or without
additional cusp repair.
Methods: 125 patients with aortic root aneurysms underwent the Remod-
eling technique combined with a subvalvular annuloplasty in 10 centers (16
surgeons). Patients were analysed prospectively in 2 groups: without cusp
repair (group 1, n=80) and with cusp repair (group 2, n=45) using plicating
stitches (33), and/or running suture (10), and/or median raphe resection (12).
Results: Despite more severe preoperative aortic insufficiency (AI) in
group 2, reoperation rate was not significantly higher (table). Five over 6 reop-
erations occurred during early experience. Cusp repair rate increased from
22.3% (15) in early period to 53.4% (27, p<0.01) since 2007, when aggressive
management of cusp prolapse was started combining cusp free edges align-
ment with effective height measurement. 
Conclusion: Additional cusp repair does not affect early results of aortic
valve sparing. Standardized management of root remodeling, cusp repair and
aortic annuloplasty may improve feasibility and long term outcomes. This
approach is currently evaluated versus mechanical valve replacement by CAV-
IAAR trial (Conservative Aortic Valve surgery for aortic Insufficiency and
Aneurysms of the Aortic Root).
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Early postoperative results of De Vega tricuspid annuloplasty for tri-
cuspid regurgitation in rheumatic Mitral disease
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Objectives: Tricuspid regurgitation (TR) in patients with mitral valve
(MV) disease is associated with poor outcome and predicts poor survival, heart
failure, and reduced functional capacity.
We review our early results in patients who required surgical correction of
tricuspid valve disease with concomitant rheumatic disease of the mitral valve
operated on between 2005 and 2008.
Methods: We studied 68 consecutive patients (mean age, 32 years). All
patients were investigated perioperatively by Doppler echocardiography.
Echocardiographic assessment of tricuspid incompetence was on the basis of
gradation of tricuspid regurgitation severity according to color Doppler flow
criteria, the flow convergence region proximal to the regurgitant orifice
(PISA), the size of the tricuspid annulus, and estimation of the pulmonary
artery systolic pressure by continuous Doppler. Median tricuspid insufficiency
was 3+. Tricuspid lesions were functional in 59 patients and organic in 9
patients. The cause was rheumatic mitral valve disease in all patients. Any
patient has an aortic surgical dlession. All patients underwent De Vega tri-
cuspid annuloplasty at the time of mitral surgery.
Results: There was one operative death. Prosthetic mitral replacement was
performed in 57 patients (83.82%) and a mitral valve repair in 11 patients
(16.17%). There was 1+ or less TR in 59 patients (86.7%), moderate TR 2+ in
7 patients (10.2%) and severe TR 3+ in two patients how had a severe pulmo-
nary hypertension.
January 15th, Friday 2010
January 16th, Saturday 2010
 Group 1
without 
cusp repair
Group 2
 with 
cusp repair
Marfan 16 (20%) 2 (4.4%)*
Bicuspid valves 7 (8.8%) 19 (42.2%)*
Preoperative AI grade 1.66±1.2 (0-4) 2.42±1.2 (0-4)* 
Preoperative annulus diameter (mm) 27.5±1.6 (23-30) 28.6±2.1 (24-36)*
Operative mortality 4 (5%) 1 (2.2%)
Postoperative annulus diameter (mm) 20.1±2.1 (17-25) 21.3±1.1 (16-25)*
Post-operative AI grade 0.3±0.4 (0-1) 0.2±0.4 (0-1)
Mean follow-up (months) 36.1±21 (1-69) 17.5±16.9 (1-66)*
Freedom from AI≥grade 2 64 (94.1%) 37 (92.5%)
Reoperation for valve replacement 4 (5%) 2 (4.4%)
Survival 72 (97.3%) 42 (95.5%)
*p<0.05
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Conclusions: Aggressive repair of accompanying TR should be undertaken
at the time of initial mitral surgery. Tricuspid valve repair, described by De
Vega, is a simple, short, and inexpensive procedure with few complications.
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Objectives: What influence do patient selection and learning curve have on
the results of transapical aortic valve implantation (TAVI)?
Methods: From September 2007 to January 2009, 33 patients treated with
TAVI for severe symptomatic aortic stenosis were included in a prospective
registry. According to their risk profile, 2 patient groups were distinguished.
In Group 1 (n=25) the high surgical risk was related to technical difficulties
for conventional aortic valve replacement (porcelain aorta, redo surgery with
patent coronary artery bypass grafts, hi-dose mediastinal radiotherapy). In
Group 2 (n=8) the high risk was due to severe comorbidities.
Results: TAVI was successfully performed in all patients without per-pro-
cedural death or stroke. “Valve in valve” reimplantation was necessary in 2
patients due to persistent leaks. Mean follow-up was 10.8 months (1-17).
Overall mortality was 16% in Group 1and 37.5% in Group 2 (p=0.03). Predic-
tive factors of hospital mortality were: NYHA class (p=0.03), LV dysfunction
(p=0.009) and pulmonary hypertension (p<0.001). No reintervention, pros-
thetic valve deterioration or haemolysis was recorded. In-hospital mortality
decreased from 15.2% in the first 17 patients to 6.1% in the last 16 patients
implanted.
Conclusions: TAVI gives superior results in patients with technical diffi-
culties for conventional surgery than in patients with severe comorbidities.
These results could be improved by accumulating experience and better patient
selection.
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Accuracy of surgical scores for prediction of operative mortality in
patients undergoing transapical aortic valve implantation?
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Objective: Risk assessment for patients undergoing transapical aortic valve
implantation (TAVI) is currently performed with the EuroSCORE and STS-
PROM risk algorithms. None of these scores were designed for a TAVI pop-
ulation. To demonstrate their accuracy, both scores were compared to the real
outcome in patients undergoing TAVI.
Methods: 33 patients underwent TAVI using the Edwards Sapien biopros-
thesis between September 2007, and April 2009 due to contraindications of
conventional surgery and/or high operative risk. Mean age was 81 ± 9.8 Years,
and 40% were female. Mean STS and EuroSCORE were 21% and 28.6%,
respectively.
Multiple variables were used in the calculation of the EuroScore and the
STS-PROM algorithms including chronic lung disease (24%), renal Failure
(36.4%), cancer (27.3%), neurological dysfunction (12%), peripheral arteriop-
athy (69.7%), previous cardiac surgery (42.4%), Diabetes (30%), severe pul-
monary hypertension ≥ 60 mmHg (18.2%), moderate LV dysfunction EF≤50%
(54.6%), and LVEF ≤ 30% (21.2%). Certain variables do not figure in the
algorithm as porcelain aorta (39.4 %) and mediastinal irradiation (6%).
Observed in-hospital death was 18.2%. The actual and predicted mortality
were compared.
Results: Operative mortality (30 days) = 5 patients (15.6 %). An additional
4 patients (12.1 %) died during the follow-up study period of 587days (mean
324 ± 164). Overall mortality = 9 patients (27.3 %). Both the STS and Euro-
SCORE failed to demonstrate significant correlation with predicted operative
mortality (p=0.145 and 0.875, respectively). The STS algorithm seems more
accurate in estimating the operative mortality in TAVI patients.
Conclusion: Current surgical scores correlate poorly with the observed
outcome. Refining these scores for high risk patients requiring aortic valve
surgery may improve patient selection for TAVI.
